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The very lines inserted daily to provide nutrition to neonates during intensive care 
remain associated with real risks of both mortality and life-impacting brain injury 
from associated sepsis. But most cases of central line-associated bloodstream 
infection (CLABSI) are preventable. There is now compelling observational 
evidence that adoption of catheter-care ‘bundles’ markedly reduces rates of 
CLABSI in the NICU.[1,2] Catheter-care bundles represent grouped evidence-
based interventions for good catheter insertion and maintenance practices which, 
collectively implemented, reduce infection rates compared with individual 
component interventions. North American centres have shown that, by utilising 
bundles in conjunction with dedicated personnel, enhanced education, 
documentation, and a continuous focus on the gravity of the whole catheterisation 
process, it is possible to achieve zero CLABSI rates for protracted periods - even 
as long as 1-2 years.[3] In the most recent published UK survey, however, only 
70% of tertiary-level UK NICUs had catheter-care bundles in place.[4] Current 
evidence implies that infants cared for on Units that have not yet implemented best 
practice guidelines may be at an increased risk of CLABSI;[2] such hospitals may 
be vulnerable to possible litigation in cases of damaging late-onset sepsis. 
 
Furthermore, there is still debate as to preferred choice and accuracy of CLABSI 
working definition, inconsistency in definitions used to report CLABSI rates, and 
concern about data reliability.[2,5] The National Neonatal Audit Programme’s latest 
report (2016) shows that data entry was considered complete and reliable enough 
to allow inter-unit comparisons of CLABSI rates for only 22 (14%) of the 182 
individual NICUs audited.[5] So while many US centres have raced to slash their 
CLABSI rates, sometimes spurred on by the Medicare health insurance 
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programme’s withholding of funding for hospital-acquired CLABSI cases,[6] it 
appears that most UK units do not even know their baseline CLABSI rates with any 
degree of accuracy. Also, reflecting the most widely-used CLABSI definition,[7] 
headline CLABSI rates are currently provided only as a composite for all types of 
central catheters present. Yet umbilical catheters each have very different 
characteristics of use, dwell time, and infection risk, compared with peripherally-
inserted central venous catheters or surgical catheters. Future reporting of neonatal 
CLABSI rates should ideally include subdivisions according to catheter type to 
facilitate more valid comparisons between centres and studies.[8] 
 
Catheter-care bundles alone do not provide the complete answer to the CLABSI 
problem; they leave room for improvements which must come from careful 
research - the individual components have not been subject to rigorous evaluations 
in neonates. Arguably the most important component is the antiseptic chosen for 
skin disinfection before catheter insertion, because skin bacterial density at the 
insertion site is a major risk factor for CLABSI and the main mechanism of infection 
of short-term catheters is via extraluminal colonisation.[7,9] Major questions remain 
over the ideal antiseptic agent to use in neonates: which is the safest and most 
effective preparation to use on the vulnerable skin of preterm neonates and in what 
concentration? At the last count seven different preparations were being used in 
UK units.[4] The predominating active agent was chlorhexidine gluconate (CHG), 
with or without isopropyl alcohol, and CHG concentrations varied 133-fold (between 
0.015% and 2%). One unit was still using povidone-iodine; none was using 
octenidine, an agent popular in Europe for its supposedly better safety profile[10] 
but lacking any RCT evidence in neonates. 
 5 
 
Use of an inferior, weak antiseptic agent may be safer considering the risk of skin 
morbidity, but may confer an increased risk of life-threatening CLABSI. Conversely, 
a stronger, more effective agent may significantly reduce the risk of CLABSI but at 
the expense of an increased risk of skin chemical injury. With a dearth of guiding 
research in this area, it is welcome that two studies in the present issue now report 
on the safety and efficacy of different skin antiseptics in preterm neonates. 
 
Janssen and colleagues present retrospective observational data comparing 
CLABSI rates and skin dermatitis severity with two different CHG concentrations for 
placement of umbilical catheters and peripherally-inserted central venous catheters 
in neonates <26 weeks’ gestation. In the first epoch they used the antiseptic 
combination 0.5%CHG with 70% alcohol; in the second epoch when using 
0.2%CHG acetate alone they recorded fewer skin reactions while CLABSI rates 
stayed constant. Relative proportions of umbilical and peripheral catheters inserted 
are not detailed, though almost all skin lesions were peri-umbilical. A striking finding 
was the apparent high number of infants (7/41; 17%) with skin lesions classed 
“severe” in the first epoch. This contrasts starkly with only 4 cases of suspected 
chlorhexidine neonatal chemical skin burns/disorders (3 peri-umbilical) reported to 
Medicines and Healthcare products Regulatory Agency (MHRA) as occurring since 
its 2014 Drug Safety Update alert (Personal written communication, Vigilance and 
Risk Management of Medicines - MHRA, 17th July 2017).[11] Such wide variance 
suggests significant over-reporting, under-reporting, or both. 
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While the switch to using a lower CHG concentration and/or alcohol-free agent may 
have contributed to fewer recorded skin reactions in the second epoch, the 
reduction may just have reflected the increased awareness of antiseptic-related 
skin reactions which had prompted the unit’s change in antiseptic agent in the first 
place, perhaps coinciding with a more sparing antiseptic usage/exposure. Claiming 
that introducing the weaker, alcohol-free CHG solution resulted in a reduced 
incidence of skin lesions is unjustified. The data are of interest, but they do not 
warrant the proposal that 0.2%CHG acetate now be considered a preferred option 
for extremely preterm infants or any recommendation to change practices. For this 
was a small observational study which relied on retrospective validation of skin 
reactions and had other inherent confounders; most importantly numbers were way 
too small to detect any impact on CLABSI incidence.  
 
Kieran and colleagues deserve praise for having completed one of only very few 
antiseptic RCTs ever done in neonates for skin disinfection prior to central venous 
catheter insertion. Studying a large cohort of preterm neonates <31 weeks’ 
gestation, and with excellent follow up rates, they present data suggesting that the 
2% CHG-70% ispropyl alcohol combination seems comparable in efficacy against 
CRBSI as 10% povidone-iodine solution. As acknowledged, their main research 
question - assessing whether 2% CHG-70% ispropyl alcohol significantly reduces 
CLABSI rates compared with 10% povidone-iodine - was unfortunately unanswered 
because the study was markedly underpowered. The power calculation was based 
on very high baseline (35%) and target (20%) CLABSI rates, both much higher than 
rates actually seen in the study arms (5-7%). These figures were derived from 
historic eras with much higher rates of late-onset infection instead of from more 
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recent pre-existing local or international data for the planned study population. This 
provides another illustration of the importance of individual centres knowing their 
own accurate, up-to-date baseline CLABSI rates.  
 
The trial presents some basic safety data which suggest that a ‘stronger’ antiseptic 
(2% CHG-70% ispropyl alcohol), already shown to be superior in adults, may be 
used in preterm infants without causing significant skin injury if a strict procedure to 
limit topical application and exposure is followed. Yet the lack of robust, active 
safety surveillance by dedicated research personnel and of any prospective, routine 
recording of skin integrity and adverse reactions inevitably limits generalisability of 
safety findings. Future antiseptic studies in neonates must use appropriate 
methodology to assess skin safety outcomes rigorously, thus allowing firm 
conclusions to be drawn about the relative safety and efficacy of different antiseptic 
solutions. 
 
One important finding is that significantly more babies exposed to povidone-iodine 
antiseptic developed low thyroid status which needed treatment. Given the 
suggestion of similar efficacy of the antiseptics tested and of similar reassuring skin 
safety profiles, this finding has implications for current practice. It adds weight to 
the existing body of evidence of thyroid dysfunction in preterm neonates caused by 
topical iodine exposure,[12] and renders any ongoing use of topical iodine-based 
antiseptics very difficult to justify in preterm neonates. 
 
An important but hitherto little-considered issue concerning antiseptic safety is the 
potential for the emergence of antiseptic resistance. The global antibiotic resistance 
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crisis is widely appreciated and is a major cause of concern. Use of antiseptics to 
prevent infection developing in the first place is now more crucial than ever. 
However, there are signs that pathogens may also be evolving antiseptic 
resistance.[13] This potentially represents a huge issue given the reliance placed 
on antisepsis in many medical settings including NICUs.  
 
Bacterial resistance to antimicrobials can occur as a result of various mechanisms, 
some of which are not specific to single classes of antibiotic. For example, bacteria 
can over-produce membrane transporters that pump out multiple toxic molecules; 
often these pumps can recognise and export antiseptics as part of their repertoire. 
The ‘qac’ (quaternary ammonium compound) family of genes are known to export 
chlorhexidine and other related compounds and their presence is increasing in 
some species.[14] The clinical impact of this is however currently unclear.[15] 
There is currently no standard surveillance for antiseptic resistance in routine 
isolates and little research into the potential for different antiseptic formulations to 
select for resistance. These knowledge gaps are worrying when trying to define 
best practice for antisepsis. Future work in this area is therefore imperative to allow 
full confidence in any antiseptic agents and concentrations chosen for inclusion in 
care bundles. 
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